Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Nizar M. Tannir, Thomas Powles, Bernard J. Escudier, Frede Donskov, Viktor Grünwald, Cora N. Sternberg, Manuela Schmidinger, Patrick Schoffski, Cezary Szczylik, Katriina Johanna Peltola, Dmitry Nosov, Bohuslav Melichar, Douglas O. Clary, Christian Scheffold, Robert J. Motzer, Toni K. Choueiri
Institutions: The University of Texas MD Anderson Cancer Center, Barts Cancer Institute, Institut Gustave Roussy, Aarhus University Hospital, Medizinische Hochschule Hannover, Azienda Ospedaliera San Camillo-Forlanini, Medical University of Vienna, KU Leuven, Wojskowy Instytut Medyczny, Helsinki University Hospital, Russian Cancer Research Center NN Blokhin, Palacký University Olomouc, Exelixis (United States), Memorial Sloan Kettering Cancer Center, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891251027